---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088200"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:25:10.765622+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA enters option/license deal with Biocytogen for B7H3/PTK7 BsADC; total potential $406.5M

## Summary
- Total potential payments of $406.5M including $100M development/regulatory milestones and single-digit royalties.
- Option for exclusive worldwide license; upfront and option exercise fees up to $6.5M.
- Targets B7H3/PTK7 co-expression in lung, colorectal, head and neck cancers with double-digit prevalence.
- Development candidate nomination targeted for H2 2024; potential combo with DDR pipeline including IDE161 (PARG).

## SEC filing metadata
- accession: 0000950170-24-088200
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024088200/0000950170-24-088200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024088200/idya-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088200
- JSON: https://secwatch.observer/filing/0000950170-24-088200.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.